This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
Non-muscle Invasive Bladder Cancer
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
Alaska Clinical Research Center, Anchorage, Alaska, United States, 99503
Arkansas Urology, Little Rock, Arkansas, United States, 72211
Hoag Cancer Center, Irvine, California, United States, 92618
UCLA Department of Urology, Los Angeles, California, United States, 90095
University of California, Davis, Sacramento, California, United States, 95817
Skyline Sherman Oaks, Sherman Oaks, California, United States, 91411
Skyline Urology, Torrance, California, United States, 90505
Eastern Connecticut Hematology & Oncology Associates, Norwich, Connecticut, United States, 06360
Clinical Research Center of Florida, Pompano Beach, Florida, United States, 33060
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
ImmunityBio, Inc.,
Bobby Reddy, MD, STUDY_DIRECTOR, ImmunityBio, Inc.
2038-12